Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 160,400 Shares

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 160,400 shares of Invivyd stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the transaction, the director now owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. The trade was a 3.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Trading Down 2.7 %

IVVD stock opened at $0.58 on Thursday. Invivyd, Inc. has a 12-month low of $0.57 and a 12-month high of $5.20. The stock has a market cap of $69.86 million, a price-to-earnings ratio of -0.30 and a beta of 0.53. The business’s 50-day moving average is $0.85 and its 200 day moving average is $1.08.

Analyst Upgrades and Downgrades

IVVD has been the subject of several recent analyst reports. Morgan Stanley cut their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. HC Wainwright cut their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Invivyd currently has a consensus rating of “Buy” and a consensus price target of $7.89.

Institutional Investors Weigh In On Invivyd

Institutional investors have recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in Invivyd in the 3rd quarter worth about $27,000. SG Americas Securities LLC boosted its holdings in shares of Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after purchasing an additional 25,201 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new position in shares of Invivyd during the 2nd quarter worth approximately $86,000. Finally, Rhumbline Advisers boosted its holdings in shares of Invivyd by 4,434.1% during the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.